To further demonstrate the specificity of the SH2-based biosensor BRET signals, we monitored the inhibitory action of Gefitinib (IressaTM), an EGFR-specific tyrosine kinase inhibitor (TKI), commonly used as a first-line treatment for some breast and lung cancers. This evidence concerns the gene EGFR and lung cancer.